UOC
ACAD icon

UBS O'Connor’s Acadia Pharmaceuticals ACAD Stock Holding History

UBS O'Connor’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-43,000
Closed -$928K – 277
2025
Q2 		$928K Buy
+43,000
New +$799K 0.03% 228
2016
Q2 		– Sell
-21,582
Closed -$603K – 398
2016
Q1 		$603K Buy
+21,582
New +$471K 0.01% 385
2014
Q2 		– Sell
-30,000
Closed -$730K – 433
2014
Q1 		$730K Buy
+30,000
New +$759K 0.01% 339

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

UBS O'Connor's ACAD Position: Q3 2025 in Review

UBS O'Connor sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 43,000 shares — an estimated $928K sold.

UBS O'Connor first reported a position in ACAD in Q1 2014 and held it in 3 quarters. The position peaked at $928K in Q2 2025. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • UBS O'Connor reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 43,000 Acadia Pharmaceuticals shares in Q3 2025, an estimated $928K.
  • UBS O'Connor first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • UBS O'Connor's Acadia Pharmaceuticals position peaked at $928K in Q2 2025.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.